title: Heart Peptide Hormones: Adjunct and Primary Treatments of Cancer.
abstract: Four heart hormones, namely atrial natriuretic peptide (ANP), long-acting natriuretic peptide (LANP), vessel dilator and kaliuretic peptide reduce up to 97% of cancer cells in vitro. These four cardiac hormones eliminate up to 80% of human pancreatic adenocarcinomas, two-thirds of human breast carcinomas and up to 86% of human small-cell lung carcinomas growing in athymic mice. ANP given intravenously for 3 hours after 'curative' lung surgery as an adjunct to surgery results in a 2-year relapse-free survival of 91% compared to 75% for those treated with surgery alone. The anticancer mechanisms of action of these peptides involve binding to receptors on the cancer cells, followed by 95% inhibition of the conversion of inactive to active rat sarcoma-bound guanosine triphosphate (RAS)-mitogen-activated protein kinase (MAPK) kinases 1/2 (MEK 1/2) (98% inhibition)-extracellular signal-related kinases 1/2 (ERK1/2) (96% inhibition) cascade in cancer cells. They are dual inhibitors of vascular endothelial growth factor (VEGF) and its VEGF2 receptor (up to 89%). They also inhibit MAPK9, i.e. c-JUN-N-terminal kinase 2. One of the downstream targets of VEGF is β-catenin, which these peptides inhibit by up to 88%. These four peptide hormones inhibit the Wingless-related integration site (WNT) pathway 68% and WNT secreted-Frizzled protein is reduced by up to 84%. Signal transducer and activator of transcription 3 (STAT3), a final 'switch' that activates gene expression that leads to malignancy, is specifically reduced up to 88% by these peptides but they do not affect STAT1. There is crosstalk between the RAS-MEK 1/2-ERK 1/2 kinase cascade, VEGF, β-catenin, JNK, WNT, and STAT pathways and each of these pathways and their crosstalk is inhibited by these peptide hormones. They enter the nucleus of cancer cells where they inhibit the proto-oncogenes c-FOS (by up to 82%) and c-JUN (by up to 61%).
  
  
  
  These multiple kinase inhibitors have both adjunct and primary anticancer effects.
authors: Departments of Medicine, Molecular Pharmacology and Physiology, University of South Florida Morsani School of Medicine, Tampa, FL, U.S.A. david.tampabay@gmail.com.
authors: David L
authors: DL
authors: Vesely
mesh_terms: D000818:Animals; D018572:Disease-Free Survival; D006801:Humans; D051379:Mice; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D036361:Peptide Hormones / Q000627:therapeutic use*
chemical_list: D036361:Peptide Hormones
keywords: Adjunct therapy; mechanisms of action; metastasis; method of treatment; new therapeutics; peptides; primary therapy; review